<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537508</url>
  </required_header>
  <id_info>
    <org_study_id>MET42</org_study_id>
    <secondary_id>U1111-1183-6361</secondary_id>
    <nct_id>NCT03537508</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</brief_title>
  <official_title>A Phase III, Partially Modified Double-blind, Randomized, Parallel-group, Active-controlled, Multi-center Study to Compare the Immunogenicity and Describe the Safety of MenACYW Conjugate Vaccine and MENVEO® When Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the immunogenicity and describe the safety of MenACYW&#xD;
      conjugate vaccine and MENVEO® when both are administered concomitantly with routine pediatric&#xD;
      vaccines to healthy infants and toddlers in the US.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of each subject's participation in the trial will be approximately 16 to 19&#xD;
      months (Subgroup 1a) and 19 to 22 months (Subgroup 1b and Group 2), which includes a safety&#xD;
      follow up contact at 6 months after the last vaccinations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2018</start_date>
  <completion_date type="Anticipated">September 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The study is conducted modified double blind for the infant part of the study, with everyone involved in the study (participants/parents, investigators, safety outcome assessor, Sponsor) blinded to the meningococcal vaccine received, except the personnel administering the vaccine.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody titers above predefined thresholds against meningococcal serogroups A, C, Y, and W (Subgroup 1a and 2a)</measure>
    <time_frame>D0 and 30 days after the fourth meningococcal vaccination for subgroup 1a and 2a</time_frame>
    <description>Percentage of participants achieving a seroresponse, measured by the serum bactericidal assay using human complement (hSBA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody titers ≥ 1:8 against meningococcal serogroups A, C, Y, and W (group 1 and 2)</measure>
    <time_frame>30 days after vaccination at 6 months of age for group 1 and 2</time_frame>
    <description>Percentage of participants achieving antibody titers ≥ predefined threshold of 1:8, measured by hSBA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IgG antibody concentrations ≥ 10 milli-international units (mIU) / mL against hepatitis B</measure>
    <time_frame>30 days after vaccination at 6 months of age for group 1 and 2</time_frame>
    <description>Percentage of participants who achieving IgG antibody concentrations ≥ predefined threshold of 10 mIU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG antibody concentrations against hepatitis B</measure>
    <time_frame>30 days after vaccination at 6 months of age for group 1 and group 2</time_frame>
    <description>Antibody concentrations will be measured by standard assays for the antigens contained in the vaccine and expressed as geometric mean concentrations (GMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations against polyribosyl-ribitol phosphate (PRP)</measure>
    <time_frame>30 days after vaccination at 6 months, before and 30 days after 15-months vaccination for subgroup 1b and 2b</time_frame>
    <description>Antibody concentrations will be measured by standard assays for the antigens contained in the vaccine and expressed as geometric mean concentrations (GMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations ≥ 0.15 and/or ≥ 1.0 µg/mL against PRP</measure>
    <time_frame>30 days after vaccination at 6 months of age for group 1 and group 2, before and 30 days after vaccination at 15 months of age for subgroup 1b and 2b</time_frame>
    <description>Percentage of subjects achieving antibody concentrations ≥ predefined thresholds of 0.15 µg/mL and/or 1.0 µg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations above predefined threshold against diphteria and tetanus</measure>
    <time_frame>30 days after vaccination at 6 months for group 1 and 2, 30 days after 15-months vaccination for subgroup 1b and 2b</time_frame>
    <description>% of participants with antibody concentrations ≥ established serostatus cut-off levels for diphteria and tetanus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations against diphteria and tetanus</measure>
    <time_frame>30 days after vaccination at 6 months for group 1 and 2, 30 days after 15-months vaccination for subgroup 1b and 2b</time_frame>
    <description>Antibody concentrations will be measured by standard assays for the antigens contained in the vaccine and expressed as geometric mean concentrations (GMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers ≥ 1:8 against poliovirus types 1, 2, and 3</measure>
    <time_frame>30 days after vaccination at 6 months for group 1 and group 2, 30 days after vaccination at 15 months of age for subgroup 1b and 2b</time_frame>
    <description>Percentage of participants achieving antibody titers ≥ predefined threshold of 1:8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers against poliovirus types 1,2,3</measure>
    <time_frame>30 days after vaccination at 6 months of age for group 1 and group 2, 30 days after vaccination at 15 months of age for subgroup 1b and 2b</time_frame>
    <description>Antibody titers will be measured by standard assays for the antigens contained in the vaccine and expressed as geometric mean titers (GMTs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgA antibody concentrations with ≥ 3-fold rise over baseline for antigens of 5 serogroups of rotavirus</measure>
    <time_frame>D0 and 30 days after vaccination at 6 months of age for group 1 and 2</time_frame>
    <description>Percentage of participants achieving IgA antibody concentrations ≥ predefined threshold of 3-fold rise over baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgA antibody concentrations against antigens of 5 serogroups of rotavirus</measure>
    <time_frame>D0 and 30 days after vaccination at 6 months of age for group 1 and 2</time_frame>
    <description>Antibody concentrations will be measured by standard assays for the antigens contained in the rotavirus vaccine and expressed as geometric mean concentrations (GMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations against pertussis (pertussis toxoid [PT], filamentous hemagglutinin [FHA], pertactin [PRN], fimbriae types 2 and 3 [FIM])</measure>
    <time_frame>D0 and 30 days after vaccination at 6- months of age for group 1 and 2, before and after the 15-months vaccinations for subgroup 1b and 2b</time_frame>
    <description>Antibody concentrations will be measured by standard assays for the antigens contained in the vaccine and expressed as geometric mean concentrations (GMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations above predefined threshold against pertussis (PT, FHA, PRN, FIM)</measure>
    <time_frame>before and after the vaccination at 15 months of age for subgroup 1b and 2b</time_frame>
    <description>% of participants with antibody concentrations ≥ established seroresponse rate for pertussis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations against antigens of 13-valent pneumococcal vaccine</measure>
    <time_frame>30 days after vaccination at 6 months for group 1 and 2, 30 days after vaccination at 12 months for subgroup 1a and 2a</time_frame>
    <description>Antibody concentrations will be measured by standard assays for the antigens contained in the vaccine and expressed as geometric mean concentrations (GMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations above predefined thresholds for antigens of MMR vaccine</measure>
    <time_frame>30 days after the 12-month vaccination for subgroup 1a and 2a</time_frame>
    <description>% of participants with antibody concentrations ≥ established serostatus cut-off levels for antigens in MMR vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations against antigens of MMR vaccine</measure>
    <time_frame>30 days after the 12-month vaccination for subgroup 1a and 2a</time_frame>
    <description>Antibody concentrations will be measured by standard assays for the antigens contained in the vaccine and expressed as geometric mean concentrations (GMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations against antigens of varicella vaccine</measure>
    <time_frame>30 days after the 12-month vaccination for subgroup 1a and 2a</time_frame>
    <description>Antibody concentrations will be measured by standard assays for the antigens contained in the vaccine and expressed as geometric mean concentrations (GMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody concentrations above predefined thresholds for antigens of varicella vaccine</measure>
    <time_frame>30 days after the 12-month vaccination for subgroup 1a and 2a</time_frame>
    <description>% of participants with antibody concentrations ≥ established serostatus cut-off levels for antigens in varicella vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody against meningococcal serogroups A, C, Y, and W</measure>
    <time_frame>D0, 30 days after the 6-month age vaccination for group 1 and 2, before and 30 days after the 12-month vaccination for subgroup 1a and 2a, before and after the 15-month vaccination for subgroup 1b</time_frame>
    <description>Antibody titers will be measured by hSBA and expressed as geometric mean titers (GMTs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers above pre-defined thresholds for meningococcal serogroups A, C, Y, and W</measure>
    <time_frame>30 days after the 6-month age vaccination for group 1 and 2, before and 30 days after the 12-month vaccination for subgroup 1a and 2a, before and after the 15-month vaccination for subgroup 1b</time_frame>
    <description>% of participants achieving antibody titers ≥ predefined thresholds, measured by hSBA</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2628</enrollment>
  <condition>Healthy Volunteers (Meningococcal Infection)</condition>
  <arm_group>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MenACYW conjugate vaccine and routine vaccines at 2, 4, 6, and 12 to 15 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MenACYW conjugate vaccine at 2, 4, 6, and 15 to 18 months of age and routine vaccines at 2, 4, 6, 12 to 15 months of age, and 15 to 18 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACYW conjugate vaccine</intervention_name>
    <description>Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular</description>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_label>Group 1b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACYW-135 conjugate vaccine</intervention_name>
    <description>Meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, 0.5 mL, intramuscular</description>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <other_name>MENVEO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV//Hib vaccine</intervention_name>
    <description>DTaP-IPV//Hib vaccine at 2, 4, and 6 months of age, Intramuscular</description>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <other_name>Pentacel®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal 13-valent conjugate vaccine</intervention_name>
    <description>Pneumococcal vaccine at 2, 4, 6, and 12 months of age, Intramuscular</description>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <other_name>PREVNAR 13®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pentavalent rotavirus vaccine</intervention_name>
    <description>Rotavirus vaccine at 2, 4, and 6 months of age, oral solution</description>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <other_name>RotaTeq®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B vaccine</intervention_name>
    <description>Hepatitis B vaccine at 2 and 6 months of age, Intramuscular</description>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <other_name>ENGERIX-B®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles, mumps, rubella (MMR) vaccine</intervention_name>
    <description>MMR vaccine at 12 months of age, Subcutaneous</description>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <other_name>M-M-R® II</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Varicella vaccine</intervention_name>
    <description>Varicella vaccine at 12 months of age</description>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <other_name>VARIVAX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis A vaccine</intervention_name>
    <description>Hepatitis A vaccine at 15 to 18 months of age</description>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <other_name>HAVRIX®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥ 42 to ≤ 89 days on the day of the first study visit.&#xD;
&#xD;
          -  Healthy infants as determined by medical history, physical examination, and judgment&#xD;
             of the investigator&#xD;
&#xD;
          -  Informed consent form has been signed and dated by the parent(s) or guardian, and an&#xD;
             independent witness, if required by local regulations&#xD;
&#xD;
          -  Participant and parent/guardian are able to attend all scheduled visits and to comply&#xD;
             with all trial procedures.&#xD;
&#xD;
          -  Infants who received the first dose of hepatitis B vaccine at least 28 days before the&#xD;
             first study visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation at the time of study enrollment or in the 4 weeks preceding the first&#xD;
             trial vaccination or planned participation during the present trial period in another&#xD;
             clinical trial investigating a vaccine, drug, medical device, or medical procedure&#xD;
&#xD;
          -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned&#xD;
             receipt of any vaccine in the 4 weeks before and/or following any trial vaccination&#xD;
             except for influenza vaccination, which may be received at a gap of at least 2 weeks&#xD;
             before or 2 weeks after any study vaccination. This exception includes monovalent&#xD;
             pandemic influenza vaccines and multivalent influenza vaccines&#xD;
&#xD;
          -  Previous vaccination against meningococcal disease with either the trial vaccine or&#xD;
             another vaccine (i.e., mono- or polyvalent, PS, or conjugate meningococcal vaccine&#xD;
             containing serogroups A, C, Y, or W; or meningococcal B serogroup-containing vaccine).&#xD;
&#xD;
          -  Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis&#xD;
             A, measles, mumps, rubella, varicella; and of Haemophilus influenzae type b,&#xD;
             Streptococcus pneumoniae, and /or rotavirus infection or disease&#xD;
&#xD;
          -  Receipt of more than 1 previous dose of hepatitis B vaccine&#xD;
&#xD;
          -  Receipt of immune globulins, blood, or blood-derived products since birth&#xD;
&#xD;
          -  Known or suspected congenital or acquired immunodeficiency; or receipt of&#xD;
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or&#xD;
             long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2&#xD;
             consecutive weeks) since birth&#xD;
&#xD;
          -  Family history of congenital or hereditary immunodeficiency, until the immune&#xD;
             competence of the potential vaccine recipient is demonstrated&#xD;
&#xD;
          -  Individuals with blood dyscrasias, leukemia, lymphoma of any type, or other malignant&#xD;
             neoplasms affecting the bone marrow or lymphatic systems&#xD;
&#xD;
          -  Individuals with active tuberculosis&#xD;
&#xD;
          -  History of any Neisseria meningitidis infection, confirmed either clinically,&#xD;
             serologically, or microbiologically&#xD;
&#xD;
          -  History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, hepatitis A,&#xD;
             measles, mumps, rubella, varicella; and of Haemophilus influenzae type b,&#xD;
             Streptococcus pneumoniae, and /or rotavirus infection or disease&#xD;
&#xD;
          -  At high risk for meningococcal infection during the trial (specifically, but not&#xD;
             limited to, subjects with persistent complement deficiency, with anatomic or&#xD;
             functional asplenia, or subjects travelling to countries with high endemic or epidemic&#xD;
             disease)&#xD;
&#xD;
          -  History of intussusception&#xD;
&#xD;
          -  History of any neurologic disorders, including any seizures and progressive neurologic&#xD;
             disorders&#xD;
&#xD;
          -  History of Guillain-Barré syndrome&#xD;
&#xD;
          -  Known systemic hypersensitivity to any of the vaccine components or to latex, or&#xD;
             history of a life-threatening reaction to the vaccine(s) used in the trial or to a&#xD;
             vaccine containing any of the same substances, including neomycin, gelatin, and yeast&#xD;
&#xD;
          -  Verbal report of thrombocytopenia contraindicating intramuscular vaccination in the&#xD;
             investigator's opinion&#xD;
&#xD;
          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,&#xD;
             contraindicating intramuscular vaccination in the investigator's opinion&#xD;
&#xD;
          -  Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first&#xD;
             blood draw&#xD;
&#xD;
          -  Chronic illness (including, but not limited to, cardiac disorders, congenital heart&#xD;
             disease, chronic lung disease, renal disorders, auto-immune disorders, diabetes,&#xD;
             psychomotor diseases, and known congenital or genetic diseases) that in the opinion of&#xD;
             the investigator, is at a stage where it might interfere with trial conduct or&#xD;
             completion&#xD;
&#xD;
          -  Any condition which, in the opinion of the investigator, might interfere with the&#xD;
             evaluation of the study objectives&#xD;
&#xD;
          -  Moderate or severe acute illness/infection (according to investigator judgment) on the&#xD;
             day of vaccination or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]). A&#xD;
             prospective participant should not be included in the study until the condition has&#xD;
             resolved or the febrile event has subsided&#xD;
&#xD;
          -  Identified as a natural or adopted child of the investigator or employee with direct&#xD;
             involvement in the proposed study&#xD;
&#xD;
          -  The above information is not intended to contain all considerations relevant to a&#xD;
             patient's potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>89 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency Toll free number for US &amp; Canada - e-mail is recommended)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number :8400026</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400003</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400083</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400011</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400032</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400031</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400007</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400092</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400126</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400095</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400030</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400076</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400077</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400057</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400014</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400040</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400063</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400068</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400001</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400108</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400022</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400064</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400132</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400008</name>
      <address>
        <city>Chamblee</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400073</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400106</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400010</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400043</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400142</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400023</name>
      <address>
        <city>Haughton</city>
        <state>Louisiana</state>
        <zip>71037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400025</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400120</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400004</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400041</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400080</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39531</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400037</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400039</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400137</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400100</name>
      <address>
        <city>Boone</city>
        <state>North Carolina</state>
        <zip>28607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400084</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400002</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45419</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400085</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400047</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400005</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400110</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400033</name>
      <address>
        <city>Tullahoma</city>
        <state>Tennessee</state>
        <zip>37388</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400059</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78726</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400065</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400075</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400079</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107-2699</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400067</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0163</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400109</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400114</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77087</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400053</name>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400049</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400128</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400016</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400035</name>
      <address>
        <city>Kaysville</city>
        <state>Utah</state>
        <zip>84037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400018</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400024</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400056</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400029</name>
      <address>
        <city>Roy</city>
        <state>Utah</state>
        <zip>84067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400038</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400036</name>
      <address>
        <city>Syracuse</city>
        <state>Utah</state>
        <zip>84075-9645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400062</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6300116</name>
      <address>
        <city>Caguas</city>
        <zip>00726</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6300122</name>
      <address>
        <city>Guayama</city>
        <zip>000784</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6300015</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6300117</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6300140</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 27, 2021</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal meningitis</keyword>
  <keyword>MenACYW conjugate vaccine</keyword>
  <keyword>Quadrivalent meningococcal vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

